{"id":"placebo-every-4-weeks","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance administered in blinded clinical trials to establish a baseline for comparison against active drug treatments. It allows researchers to distinguish genuine drug efficacy from placebo response and natural disease progression. The every-4-weeks dosing schedule matches the active comparator arm in this Phase 3 trial.","oneSentence":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:59.305Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07149649","phase":"PHASE2, PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":230},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06727552","phase":"PHASE2","title":"A Study of Barzolvolimab in Patients With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-12-18","conditions":"Atopic Dermatitis","enrollment":131},{"nctId":"NCT05142735","phase":"NA","title":"Effects of NAC on Symptoms of CHR Patients","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-13","conditions":"Prodromal Schizophrenia","enrollment":90},{"nctId":"NCT06616974","phase":"PHASE2","title":"A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)","status":"RECRUITING","sponsor":"Tectonic Therapeutic","startDate":"2024-09-04","conditions":"Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction","enrollment":180},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT05287113","phase":"PHASE2","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences International Sàrl","startDate":"2022-11-14","conditions":"Head and Neck Cancer","enrollment":176},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT07266402","phase":"PHASE3","title":"A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)","status":"RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2026-01-15","conditions":"Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria","enrollment":240},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT06445023","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":963},{"nctId":"NCT06123754","phase":"PHASE3","title":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2023-11-17","conditions":"Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT06603077","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avalo Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Hidradenitis Suppurativa","enrollment":250},{"nctId":"NCT06455202","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-19","conditions":"Chronic Spontaneous Urticaria","enrollment":976},{"nctId":"NCT06247345","phase":"PHASE1","title":"A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01","status":"SUSPENDED","sponsor":"Alzheimer's Disease Expert Lab (ADEL), Inc.","startDate":"2024-02-06","conditions":"Alzheimer Disease","enrollment":73},{"nctId":"NCT06611163","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2025-03-21","conditions":"Moderate to Severe Genital Psoriasis","enrollment":206},{"nctId":"NCT07492446","phase":"NA","title":"Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Istanbul Sabahattin Zaim University","startDate":"2025-05-09","conditions":"Recovery Methods, Exercise and Recovery, Exercise Fatigue","enrollment":30},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT06989437","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":982},{"nctId":"NCT07218445","phase":"PHASE4","title":"The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-04","conditions":"Obesity, Menopause Hot Flashes","enrollment":40},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT03997786","phase":"PHASE2, PHASE3","title":"A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-01-15","conditions":"Moderate-to-severe Chronic Plaque Psoriasis","enrollment":135},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT05548556","phase":"PHASE2","title":"A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-02-07","conditions":"Facioscapulohumeral Muscular Dystrophy (FSHD)","enrollment":51},{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT04763343","phase":"PHASE3","title":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","sponsor":"Tatiana Falcone, MD","startDate":"2022-06-27","conditions":"Suicide, Attempted","enrollment":60},{"nctId":"NCT07281495","phase":"PHASE2","title":"Taldefgrobep Alfa in Adults With Overweight and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2025-11-24","conditions":"Obesity, Overweight","enrollment":150},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT03367403","phase":"PHASE2","title":"A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-18","conditions":"Alzheimer Disease","enrollment":272},{"nctId":"NCT04944836","phase":"PHASE2","title":"Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-03-09","conditions":"Rotator Cuff Tears","enrollment":58},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT03875235","phase":"PHASE3","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-16","conditions":"Biliary Tract Neoplasms","enrollment":810},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT07441252","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-03-05","conditions":"Overweight or Obesity and Elevated Liver Fat","enrollment":180},{"nctId":"NCT06378697","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2023-11-22","conditions":"Ankylosing Spondylitis","enrollment":510},{"nctId":"NCT04639050","phase":"PHASE1, PHASE2","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-15","conditions":"Alzheimers Disease","enrollment":241},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT06113328","phase":"PHASE2","title":"A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-27","conditions":"Non-segmental Vitiligo","enrollment":169},{"nctId":"NCT04191499","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-29","conditions":"Breast Cancer","enrollment":325},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT04119050","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-08-15","conditions":"Warm Autoimmune Hemolytic Anemia","enrollment":118},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT06736990","phase":"PHASE2","title":"A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Calluna Pharma AS","startDate":"2025-06-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":150},{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400},{"nctId":"NCT07033494","phase":"PHASE2","title":"A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Early Alzheimer's Disease","enrollment":340},{"nctId":"NCT06705764","phase":"PHASE4","title":"Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-04-01","conditions":"Severe Asthma","enrollment":100},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT04033445","phase":"PHASE2, PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-26","conditions":"Ulcerative Colitis","enrollment":1064},{"nctId":"NCT07468552","phase":"PHASE2","title":"Trial of Tirzepatide for the Treatment of Cannabis Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-11-15","conditions":"Cannabis Use Disorder","enrollment":100},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT04179175","phase":"PHASE3","title":"Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-03-18","conditions":"Hidradenitis Suppurativa","enrollment":703},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05622708","phase":"PHASE4","title":"A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-28","conditions":"Non-radiographic Axial Spondyloarthritis","enrollment":240},{"nctId":"NCT06979375","phase":"PHASE2","title":"A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-30","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT06499285","phase":"PHASE3","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-06","conditions":"Myelodysplastic Syndromes","enrollment":225},{"nctId":"NCT06641089","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","status":"RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":600},{"nctId":"NCT06042478","phase":"PHASE3","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-15","conditions":"Chronic Spontaneous Urticaria","enrollment":470},{"nctId":"NCT06979362","phase":"PHASE2","title":"A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-27","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT07462130","phase":"PHASE1, PHASE2","title":"An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-03-01","conditions":"Thyroid Eye Disease","enrollment":74},{"nctId":"NCT04205812","phase":"PHASE3","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2020-09-11","conditions":"Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer","enrollment":583},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT06144710","phase":"PHASE1","title":"SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2023-11-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":48},{"nctId":"NCT05104476","phase":"PHASE2","title":"A Study of Lu AF82422 in Participants With Multiple System Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lundbeck A/S","startDate":"2021-11-16","conditions":"Multiple System Atrophy","enrollment":64},{"nctId":"NCT04777331","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-05","conditions":"Parkinsons Disease","enrollment":586},{"nctId":"NCT05767034","phase":"PHASE3","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-22","conditions":"Polymyalgia Rheumatica","enrollment":381},{"nctId":"NCT05503264","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-09-27","conditions":"NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis","enrollment":152},{"nctId":"NCT05481879","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1","status":"RECRUITING","sponsor":"Dyne Therapeutics","startDate":"2022-09-05","conditions":"Myotonic Dystrophy Type 1 (DM1)","enrollment":116},{"nctId":"NCT06864104","phase":"PHASE2","title":"A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kardigan, Inc.","startDate":"2025-04-10","conditions":"Hypertension","enrollment":206},{"nctId":"NCT06165341","phase":"PHASE3","title":"Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-03-01","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":50},{"nctId":"NCT05677971","phase":"PHASE3","title":"Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-03-06","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":160},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT01767311","phase":"PHASE2","title":"A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-12-20","conditions":"Alzheimer's Disease","enrollment":856},{"nctId":"NCT06826196","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata","status":"RECRUITING","sponsor":"Aldena Therapeutics","startDate":"2025-03-24","conditions":"Alopecia Areata (AA)","enrollment":24},{"nctId":"NCT05727384","phase":"PHASE2","title":"Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anne B. Newman","startDate":"2023-08-01","conditions":"Inflammation, Frailty","enrollment":29},{"nctId":"NCT00433511","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-02","conditions":"Breast Adenocarcinoma","enrollment":4994},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07010159","phase":"PHASE2, PHASE3","title":"Phase 2/3 Study of KPL-387 in Recurrent Pericarditis","status":"RECRUITING","sponsor":"Kiniksa Pharmaceuticals International, plc","startDate":"2025-07-25","conditions":"Pericarditis, Pericarditis Acute, Recurrent Pericarditis","enrollment":165},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT07442786","phase":"NA","title":"Clustered tDCS Sessions for Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2026-04","conditions":"Chronic Alcohol Use Disorder","enrollment":312},{"nctId":"NCT06667453","phase":"PHASE2","title":"A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1","status":"RECRUITING","sponsor":"PepGen Inc","startDate":"2024-12-10","conditions":"Myotonic Dystrophy 1","enrollment":24},{"nctId":"NCT06934252","phase":"PHASE1","title":"Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients","status":"RECRUITING","sponsor":"TRex Bio, Inc.","startDate":"2025-05-02","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":115},{"nctId":"NCT03706690","phase":"PHASE3","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":407},{"nctId":"NCT05380453","phase":"PHASE3","title":"Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-09-29","conditions":"Giant Cell Arteritis","enrollment":151},{"nctId":"NCT07435129","phase":"PHASE2","title":"Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD","status":"NOT_YET_RECRUITING","sponsor":"Scholar Rock, Inc.","startDate":"2026-08","conditions":"Facioscapulohumeral Muscular Dystrophy, FSHD","enrollment":60},{"nctId":"NCT06136741","phase":"PHASE2","title":"A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nektar Therapeutics","startDate":"2023-11-15","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":396}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1521,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Here's a 2-sentence factual summary of Placebo every 4 weeks:\n\n**Week 1**\nPlacebo is a control intervention used in clinical trials to compare the effects of a treatment against a standard or inactive treatment. In clinical trials, Placebo has been used to study various conditions, including Persistent Allergic Asthma, Limited-Stage Small Cell Lung Cancer, and Crohn's Disease With Perianal Fistulas.\n\n**Week 5**\nPlacebo is used as a control intervention in clinical trials to evaluate the efficacy of treatments, such as Omalizumab, in conditions like Persistent Allergic Asthma. Placebo is often used in parallel-group, double-blind, randomized studies to compare treatment outcomes.\n\n**Week 9**\nPlacebo is an inactive treatment used in clinical trials to compare the effects of a treatment against a standard or inactive treatment. In a 24-week, Phase III randomized, double-blind, placebo-controlled study, Placebo was used to evaluate the efficacy of Omalizumab in patients with Persistent Allergic Asthma.\n\n**Week 13**\nPlacebo is a control intervention used in clinical trials to compare the effects of a treatment against a standard or inactive treatment. Placebo has been used in various clinical trials, including studies on Limited-Stage Small Cell Lung Cancer and Cancer Survivors.\n\n**Week 17**\nPlacebo is used as a control intervention in clinical trials to evaluate the efficacy of treatments, such as HLX10, in conditions like Crohn's Disease With Perianal Fistulas. Placebo is often used in parallel-group, double-blind, randomized studies to compare treatment outcomes.\n\n**Week 21**\nPlacebo is an inactive treatment used in clinical trials to compare the effects of a treatment against a standard or inactive treatment. In a clinical trial, Placebo was used to study the effects of Omalizumab in patients with Persistent Allergic Asthma.\n\n**Week 25**\nPlacebo is a control intervention used","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}